Office of Research
Clinical Trials

Pancreatic Ductal- Met or unrectable

A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

This study may be approprate for those with:Metastatic Cancer

Safety and Efficacy of REGN7075 and Cemiplimab in Cancer

The primary objective of the study is: Dose Escalation: • To assess the safety and tolerability of a REGN7075 monotherapy lead-in and REGN7075 in combination with cemiplimab in patients with advanced solid tumors Dose Expansion: • To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within selected advanced solid tumor-specific cohorts, as measured by objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and/or composite response criteria

This study may be approprate for those with:Metastatic Cancer

Adding SNDX-5613 to the Standard Chemotherapy Treatment for Newly Diagnosed Patients With Acute Myeloid Leukemia

A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease.This phase Ib trial evaluates the safety, side effects, and optimal dosage of SNDX-5613 in combination with standard chemotherapy (daunorubicin and cytarabine) for patients with newly diagnosed acute myeloid leukemia (AML) harboring NPM1 or MLL/KMT2A gene mutations. SNDX-5613 inhibits specific intracellular signaling pathways essential for the survival of cancer cells. Chemotherapy agents like daunorubicin and cytarabine work by various mechanisms to halt cancer cell proliferation, either by directly killing the cells, preventing their division, or inhibiting their spread. The hypothesis is that adding SNDX-5613 to conventional chemotherapy could potentially enhance cancer control, leading to longer periods of remission or stabilization compared to chemotherapy alone.

This study may be approprate for those with:Newly Diagnosed Cancer

Efficacy and Safety of Adjuvant in Patients With Resected Pancreatic Ductal Adenocarcinoma

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

This study may be approprate for those with:Newly Diagnosed Cancer

Study on IOV-4001 for Advanced Melanoma and NSCLC

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

This study may be approprate for those with:Metastatic Cancer

A Study of LP-118 in Patients With Advanced Tumors

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects. Non Hodgkin Lymphoma Richter Transformation Multiple Myeloma T-cell-prolymphocytic Leukemia Acute Myeloid Leukemia Acute Lymphocytic Leukemia Myeodysplastic Syndrome MDS/MPN Myelofibrosis The study will start at lower doses (10 mg, 20 mg) and adopt an "accelerated titration" design for these cohorts. Once the safety of the 20 mg dose level is established, we will continue dose escalation using a classic "3+3" design to establish DLT, MTD, and RP2D, starting also with an accelerated step-up dosing schedule.

This study may be approprate for those with:Relapsed / Refractory

Contact UCCC CTO for Study Activation

Specific study details/protocols can be provided upon request

Testing a New Drug SGR-3515 for Advanced Solid Tumors

This study aims to test a new drug, SGR-3515, for treating people with advanced solid tumors. It is the first time this drug is being tried on humans, and the study will start by giving low doses to check its safety and how well people can tolerate it. Researchers will gradually increase the dose to find out the maximum amount that can be used safely. They are also looking for any side effects or toxic reactions, and how the body absorbs and responds to the drug. Additionally, they want to see how well SGR-3515 might work against these kinds of tumors. Candidates need to have a solid tumor with measurable growth and meet several health criteria to join the study. However, people with certain other conditions or those who have recently had specific treatments or surgeries cannot participate.

This study may be approprate for those with:Newly Diagnosed Cancer

ECOG ACRIN

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

This study may be approprate for those with:Newly Diagnosed Cancer

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

This study may be approprate for those with:Newly Diagnosed Cancer

Safety Study of YL211 for Advanced Solid Tumors

This clinical trial tests a new drug called YL211 to see if it's safe and effective for people with advanced solid tumors that have no other treatment options. The study is in its early stages (Phase 1) and takes place at multiple centers. There are three parts: Part 1 tests different doses to find the most tolerable dose; Part 2 checks the safety and impact in more patients; and Part 3 looks at safety and effectiveness at the chosen dose. People participating will receive the medicine intravenously and continue until conditions for stopping arise. Participants should be adults with advanced solid tumors, generally healthy apart from cancer, and must not have uncontrolled illnesses or recent allergies related to similar medicines. The study will observe any side effects, how the drug moves through the body, and how well it works against the cancer over approximately three years.

This study may be approprate for those with:Metastatic Cancer

Cordella Pulmonary Artery Sensor System to Reduce Heart Failure Hospitalizations

PROACTIVE-HF-2 is a multi-center study evaluating the Cordella™ Pulmonary Artery (PA) Sensor System in patients with chronic heart failure (NYHA Class II–III). The trial includes a randomized controlled component and a single-arm component to assess different strategies for using PA pressure data to guide outpatient HF care. Adult patients with a documented history of heart failure for at least 3 months who remain symptomatic (NYHA II–III), are on guideline-directed medical therapy, and meet biomarker and diuretic-treatment criteria are eligible if they can operate the myCordella Patient Reader and have sufficient home internet coverage. Key exclusion criteria include refractory Stage D HF, recent major cardiovascular events, severe valvular or congenital heart disease, known coagulation disorders or hypersensitivity to required antiplatelet therapy, severe comorbidity limiting survival to less than two years, or participation in another investigational trial. The implanted PA sensor continuously measures pulmonary artery pressures; clinicians receive data to inform timely adjustments in therapy aimed at reducing decompensations. Primary endpoints focus on heart failure events, HF hospitalizations, and device safety assessed through 24 months. Secondary endpoints include all-cause and cardiovascular mortality, changes in functional status and quality of life, and economic/resource utilization measured over the longer follow-up. Participants undergo baseline implantation and scheduled follow-ups with remote monitoring plus in-person visits at baseline and at 12, 24, 36, 48, and 60 months, with study duration up to 60 months. The study evaluates whether remote PA pressure-guided management using the Cordella system reduces HF hospitalizations and is safe and cost-effective in this population.

Induction Pembrolizumab in Cervical Cancer

This phase 3 study tests whether adding two cycles of pembrolizumab with carboplatin and paclitaxel before standard chemoradiation improves outcomes for people with high-risk locally advanced cervical cancer. Patients are randomly assigned to one of two groups. Arm 1 receives weekly cisplatin with radiation, pembrolizumab during chemoradiation, then pembrolizumab maintenance every 6 weeks. Arm 2 gets two cycles of induction carboplatin plus paclitaxel with pembrolizumab, then the same chemoradiation with cisplatin and pembrolizumab, followed by slightly fewer pembrolizumab maintenance doses. Patients have scans and blood tests during treatment and are followed with visits every 3 months for 2 years, then every 6 months for 3 more years. The main goal is to compare time without cancer growth (progression free survival). The study also looks at overall survival, side effects, treatment timing, tumor and blood biomarkers, and radiation quality.

This study may be approprate for those with:Recurrent Cancer

Probiotic Use During Pelvic Radiation

This is a small pilot study to see if an oral 5‑strain probiotic (Pendulum Glucose Control, or PGC) can be given safely and reliably to people getting pelvic radiation therapy. Patients who need at least 30 Gy to the pelvic lymph nodes for cancers such as anal, rectal, certain gynecologic, or node‑positive prostate cancer may join if they are adults and able to consent. The study team will track how many pills people take (pill counts at weeks 6 and 10) and will watch for side effects reported by doctors and patients. Doctors will use standard safety grading and patients will complete bowel symptom questionnaires. The study will be called feasible if most patients take at least 80% of doses and at least 70% of participants meet that adherence level. There is a 30‑day safety check after stopping the supplement. If PGC appears safe and people can take it as directed, the results could support larger randomized trials to test if the probiotic lowers radiation bowel symptoms.

This study may be approprate for those with:Newly Diagnosed Cancer

Testing New Treatment for Residual Cancer in B-cell Lymphoma Patients

This study is testing if a new experimental treatment named cemacabtagene ansegedleucel (or cema-cel for short) can help adults with large B-cell lymphoma, a type of blood cancer. Patients who have already finished one round of regular treatment and are still showing signs of leftover cancer according to a special test are being looked at. The study compares cema-cel treatment versus just watching the patients to see which helps more in preventing cancer events and eliminating leftover cancer cells. Participants must have completed standard initial therapy, be over 18, and meet certain health criteria. Those with recent other cancers or serious current infections, among other things, cannot join. The study will check for various outcomes over several months to see how well cema-cel works and note any side effects.

This study may be approprate for those with:Newly Diagnosed Cancer